http://www.bloomberg.com/news/2014-11-25/more-medicine-goes-off-limits-in-drug-price-showdown.html "payers are closely monitoring a new class of injected cholesterol drugs in late-stage testing at companies including Sanofi (SNY) and Amgen Inc.
Miller said the drugs could reach tens of billions in annual sales based on a price of $10,000 a year, which is comparable to other drugs engineered the same way, and a potential market of 10 million heart patients. "
Also mentions need for lower price HepC treatment, of course, RNAi has a solution:Regulus RG-101!